Asthma Clinical Research Studies

Treatment options for asthma continue to evolve. Currently, our center has multiple asthma studies for treatments that include: investigational inhalers for children, generic versions of already marketed medication, oral medications as add-on therapy, injections as add-on therapy, and biologics (complicated molecules that are manufactured within a living organism). Each of these asthma studies offer unique treatment opportunities for patients with mild to extremely severe asthma. These medications are provided at absolutely no cost, with no insurance needed. You may also be reimbursed for your time and travel and will receive care from physicians affiliated with the Clinical Research Center of Alabama.
For more information on any of the following asthma studies, please contact Will O’Donnell by calling 205.209.4179 or emailing

Observational Study

Age 19+


The purpose of this study is to collect information to help us understand how doctors treat and manage people with severe asthma and how the health of people with severe asthma changes with those treatments. In this study, no specific treatment or research drug is given, but your normal care and assessments are recorded. The length of each patient’s participation will vary but the goal is to have patients involved for 3 or more years.

Investigational Inhaler Study

Age 4-80


The purpose of this study is to determine if the study medication “PT027”, which is a combination of budesonide and albuterol sulfate given in a metered-dose inhaler is effective and safe for the treatment of asthma symptoms. This investigational drug combination delivers 2 well-established asthma treatments.

Investigational Biologic Study

Age 6-11

AstraZeneca TATE
The purpose of this study is to find out if the investigational medication, called Benralizumab, is safe for the treatment of severe uncontrolled asthma in children. An increase in the number of eosinophils is related to severe asthma. Eosinophils are a type of white blood cell. A signal allows eosinophils to form and become activated. This is one o f the possible causes that leads to uncontrolled asthma. It is hoped that Benralizumab will help stop that signal.

Biologic Study - Dupixent

Age 12+

Regeneron 1923
The main purpose of this study is to determine if Dupilumab (Dupixent) is effective and safe in decreasing episodes of severe breathing that you may have. Dupilumab is already approved for treatment of eczema and asthma. This study is to determine how well it treats Allergic Bronchopulmonary Aspergillosis.

Investigational biologic Study

Age 19+

teva 20031
The main purpose of this study is to evaluate the effect of TEV-48574 compared with placebo on loss of asthma control in adult patients with T2-Low and non-T2 severe asthma uncontrolled on inhaled corticosteroids.

Become a Participant in our Asthma Studies

If you’re interested in participating in a clinical research study at the Clinical Research Center of Alabama, call 205.209.4100 to speak with an experienced coordinator or fill out the contact form below.